Erythematous Plaques in a Patient on Dialysis: Direct Immunofluorescence Timing
A 54-year-old woman with end-stage renal disease on hemodialysis for 3 years presents with pruritic, violaceous, sharply demarcated plaques on the shins and forearms for 6 weeks. She takes a calcium-containing phosphate binder and an ACE inhibitor. Skin biopsy shows dermal angioplasty with fibrinoid changes and a sparse lymphocytic infiltrate; no leukocytoclasia. The pathologist considers porphyria, calciphylaxis, and nephrogenic systemic fibrosis. Serum calcium is 9.8 mg/dL, phosphate 6.1 mg/dL, PTH elevated. A fresh biopsy is requested for direct immunofluorescence (DIF).
1. How should the biopsy for DIF be handled to avoid a false-negative result, and what would you expect in porphyria?
Read the worked answer
For DIF, place the fresh specimen in Michel transport medium (or freeze promptly if available); do not place it in formalin, which can produce false-negative or uninterpretable fluorescence. In porphyria cutanea tarda, DIF typically shows homogeneous deposition of IgG, fibrin, and complement along the basement membrane zone and around dermal vessels; lesions are often on sun-exposed skin. The clinical distribution here (shins/forearms) and the histology with dermal angioplasty and fibrinoid change raise calciphylaxis, but DIF is still reasonable to exclude a pemphigoid or lupus band. The key point is that specimen handling determines whether DIF is valid.
2. How do you weigh calciphylaxis versus porphyria cutanea tarda in this patient?
Read the worked answer
Calciphylaxis is favored by ESRD, elevated phosphate and PTH, and violaceous painful plaques with fibrinoid vascular changes and minimal inflammation. Porphyria cutanea tarda would show subepidermal blisters, festooning, and solar distribution, and would be supported by urine porphyrins. The absence of leukocytoclasia and the vascular fibrinoid change in an ESRD patient point to calciphylaxis. A normal serum calcium does not exclude calciphylaxis; phosphate and PTH are more informative. The next step is clinicopathologic correlation and, if needed, urine porphyrin testing, but the working diagnosis is calciphylaxis.
3. What quality issue arises if the DIF specimen is delayed in transport?
Read the worked answer
Delayed transport can degrade immunoreactants and produce false-negative or weak staining; Michel medium preserves tissue for a limited time and should be used per laboratory protocol. If the specimen is delayed or mishandled, the result should be interpreted cautiously and a repeat biopsy considered rather than reporting a negative DIF as definitive. Document transport time and medium in the report so clinicians know the reliability of the result.